Prior to the Covid-19 pandemic, Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) licensed a few advanced-stage drugs and partnered with Regeneron Pharmaceuticals (NASDAQ:RGEN) to develop Arcalyst (rilonacept) to treat recurrent pericarditis. Kiniksa’s efforts with rilonacept succeeded but Kiniksa mostly has moved on from its earlier pipeline. At the same time, it is now collecting a 50/50 split with Regeneron on Arcalyst sales.